Quarterly report · Q2
4583.TEDINET S100OXYH
Period2022-01-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥278m | 2022-01-01 → 2022-06-30 | Standalone | Net sales |
| Revenue | ¥713m | 2021-01-01 → 2021-12-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥385m | 2021-01-01 → 2021-06-30 | Standalone | Net sales |
| Operating income | −¥779m | 2022-01-01 → 2022-06-30 | Standalone | Operating income |
| Operating income | −¥415m | 2021-01-01 → 2021-06-30 | Standalone | Operating income |
| Ordinary income | −¥769m | 2022-01-01 → 2022-06-30 | Standalone | Ordinary income |
| Ordinary income | −¥1.3bn | 2021-01-01 → 2021-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥409m | 2021-01-01 → 2021-06-30 | Standalone | Ordinary income |
| Profit before tax | −¥769m | 2022-01-01 → 2022-06-30 | Standalone | Income before income taxes |
| Profit before tax | −¥397m | 2021-01-01 → 2021-06-30 | Standalone | Income before income taxes |
| Net income | −¥771m | 2022-01-01 → 2022-06-30 | Standalone | Profit loss |
| Net income | −¥1.5bn | 2021-01-01 → 2021-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥409m | 2021-01-01 → 2021-06-30 | Standalone | Profit loss |
| Total assets | ¥1.9bn | at 2022-06-30 | Standalone | Assets |
| Total assets | ¥2.3bn | at 2021-12-31 | Standalone | Assets |
| Total assets | ¥3.3bn | at 2021-06-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥444m | at 2022-06-30 | Standalone | Liabilities |
| Total liabilities | ¥446m | at 2021-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.5bn | at 2022-06-30 | Standalone | Net assets |
| Net assets / equity | ¥1.9bn | at 2021-12-31 | Standalone | Net assets |
| Net assets / equity | ¥2.9bn | at 2021-06-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.5bn | at 2022-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2021-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.5bn | at 2022-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2021-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.3bn | at 2021-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.7bn | at 2020-12-31d | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥660m | 2022-01-01 → 2022-06-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.1bn | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥561m | 2021-01-01 → 2021-06-30 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | −¥35m | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥341m | 2022-01-01 → 2022-06-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥271m | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥176m | 2021-01-01 → 2021-06-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-18.17 | 2022-01-01 → 2022-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.53 | 2022-04-01 → 2022-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-36.74 | 2021-01-01 → 2021-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-10.16 | 2021-01-01 → 2021-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.16 | 2021-04-01 → 2021-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 75.3% | at 2022-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.4% | at 2021-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.3% | at 2021-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 43,057,600 | at 2022-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 40,781,500 | at 2021-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 40,291,500 | at 2021-06-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-06-30 | −¥239m |
| jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥691m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥278m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥278m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥151m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-01-01 → 2022-06-30 | ¥278m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-01-01 → 2022-06-30 | ¥278m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-01-01 → 2022-06-30 | −¥540m |
| Reconciling Itemsreconciling | segment profit | 2021-01-01 → 2021-06-30 | −¥215m |
| jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segment | revenue | 2021-01-01 → 2021-06-30 | ¥103m |
| jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segment | revenue external | 2021-01-01 → 2021-06-30 | ¥103m |
| jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2021-01-01 → 2021-06-30 | −¥356m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue | 2021-01-01 → 2021-06-30 | ¥282m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2021-01-01 → 2021-06-30 | ¥282m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2021-01-01 → 2021-06-30 | ¥156m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-01-01 → 2021-06-30 | ¥385m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-01-01 → 2021-06-30 | ¥385m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-01-01 → 2021-06-30 | −¥201m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 436
| Item | Context | Value | Unit |
|---|---|---|---|
| Other net ope cf | CurrentYTDDuration_NonConsolidatedMember | -20517000 | JPY |
| Subtotal ope cf | Prior1YTDDuration_NonConsolidatedMember | -564792000 | JPY |
| Subtotal ope cf | CurrentYTDDuration_NonConsolidatedMember | -656355000 | JPY |
| Interest income received ope cf | Prior1YTDDuration_NonConsolidatedMember | 13000 | JPY |
| Interest income received ope cf | CurrentYTDDuration_NonConsolidatedMember | 11000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration_NonConsolidatedMember | -636000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration_NonConsolidatedMember | -645000 | JPY |
| Income taxes paid ope cf | Prior1YTDDuration_NonConsolidatedMember | -13494000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration_NonConsolidatedMember | -3240000 | JPY |
| Income taxes refund ope cf | Prior1YTDDuration_NonConsolidatedMember | 18053000 | JPY |
| Income taxes refund ope cf | CurrentYTDDuration_NonConsolidatedMember | 4000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration_NonConsolidatedMember | -560856000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration_NonConsolidatedMember | -660225000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration_NonConsolidatedMember | － | JPY |
| Increase in short term loans payable fin cf | Prior1YTDDuration_NonConsolidatedMember | 20000000 | JPY |
| Increase in short term loans payable fin cf | CurrentYTDDuration_NonConsolidatedMember | 18000000 | JPY |
| Decrease in short term loans payable fin cf | Prior1YTDDuration_NonConsolidatedMember | -10000000 | JPY |
| Decrease in short term loans payable fin cf | CurrentYTDDuration_NonConsolidatedMember | -13000000 | JPY |
| Proceeds from issuance of common stock fin cf | Prior1YTDDuration_NonConsolidatedMember | 166141000 | JPY |
| Proceeds from issuance of common stock fin cf | CurrentYTDDuration_NonConsolidatedMember | 336172000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration_NonConsolidatedMember | 176141000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration_NonConsolidatedMember | 341172000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration_NonConsolidatedMember | -384714000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration_NonConsolidatedMember | -319052000 | JPY |
| Cash and cash equivalents | Prior2YearInstant_NonConsolidatedMember | 2686318000 | JPY |
| Cash and cash equivalents | Prior1YearInstant_NonConsolidatedMember | 1790988000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant_NonConsolidatedMember | 2301603000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant_NonConsolidatedMember | 1471935000 | JPY |
| Raw materials | Prior1YearInstant_NonConsolidatedMember | 56446000 | JPY |
| Raw materials | CurrentQuarterInstant_NonConsolidatedMember | 64593000 | JPY |
| Work in process | Prior1YearInstant_NonConsolidatedMember | 2602000 | JPY |
| Work in process | CurrentQuarterInstant_NonConsolidatedMember | 1381000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | 103013000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember | 281919000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | 384932000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember | 384932000 | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | 103013000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember | 281919000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | 384932000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember | 384932000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | -356461000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember | 155931000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |